80 generics will compete fiercely over the generic market of Celebrex

It is expected that approximately 80-100 generics of the leading product recording KRW 60 billion annual sales in the non-steroidal anti-inflammatory drugs (NASIDs) market, Celebrex, will be fierce among clinic-level medical institutions from the second half of the year as the patent of the product has been expired since the 11^th.

As generic companies recognize the Celebrex market as the riche...